JP2003509038A - サブユニット最適化された融合タンパク質 - Google Patents
サブユニット最適化された融合タンパク質Info
- Publication number
- JP2003509038A JP2003509038A JP2001523619A JP2001523619A JP2003509038A JP 2003509038 A JP2003509038 A JP 2003509038A JP 2001523619 A JP2001523619 A JP 2001523619A JP 2001523619 A JP2001523619 A JP 2001523619A JP 2003509038 A JP2003509038 A JP 2003509038A
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- carcinoembryonic antigen
- sequence
- humanized anti
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 21
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 21
- 230000000694 effects Effects 0.000 claims abstract description 5
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- 239000000427 antigen Substances 0.000 description 15
- 102000036639 antigens Human genes 0.000 description 15
- 108091007433 antigens Proteins 0.000 description 15
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 102000053187 Glucuronidase Human genes 0.000 description 8
- 108010060309 Glucuronidase Proteins 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 102000011632 Caseins Human genes 0.000 description 4
- 108010076119 Caseins Proteins 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 108091023045 Untranslated Region Proteins 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 235000021247 β-casein Nutrition 0.000 description 4
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 3
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 230000003584 silencer Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 101100325793 Arabidopsis thaliana BCA2 gene Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 102100036738 Guanine nucleotide-binding protein subunit alpha-11 Human genes 0.000 description 1
- 101100283445 Homo sapiens GNA11 gene Proteins 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000402 unacceptable toxicity Toxicity 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01031—Beta-glucuronidase (3.2.1.31)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39907999A | 1999-09-17 | 1999-09-17 | |
| US09/399,079 | 1999-09-17 | ||
| PCT/US2000/025558 WO2001019842A1 (en) | 1999-09-17 | 2000-09-18 | Subunit optimized fusion proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003509038A true JP2003509038A (ja) | 2003-03-11 |
| JP2003509038A5 JP2003509038A5 (enExample) | 2005-11-17 |
Family
ID=23578058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001523619A Pending JP2003509038A (ja) | 1999-09-17 | 2000-09-18 | サブユニット最適化された融合タンパク質 |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1237900A4 (enExample) |
| JP (1) | JP2003509038A (enExample) |
| KR (1) | KR20020039346A (enExample) |
| CN (1) | CN1379782A (enExample) |
| AU (1) | AU781462B2 (enExample) |
| BR (1) | BR0014524A (enExample) |
| CA (1) | CA2384766A1 (enExample) |
| HU (1) | HUP0202702A2 (enExample) |
| IL (1) | IL148549A0 (enExample) |
| MX (1) | MXPA02002768A (enExample) |
| NO (1) | NO20021244L (enExample) |
| NZ (1) | NZ517774A (enExample) |
| RU (1) | RU2002110116A (enExample) |
| WO (1) | WO2001019842A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030035798A1 (en) | 2000-08-16 | 2003-02-20 | Fang Fang | Humanized antibodies |
| CA2454358A1 (en) | 2001-07-19 | 2003-07-31 | Perlan Therapeutics, Inc. | Multimeric proteins and methods of making and using same |
| WO2015077071A1 (en) * | 2013-11-19 | 2015-05-28 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized b-cell activating factor gene |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL111748A0 (en) * | 1993-12-03 | 1995-01-24 | Zeneca Ltd | Proteins |
| GB9406974D0 (en) * | 1994-04-08 | 1994-06-01 | Pharmaceutical Proteins Ltd | Transgenic production |
| US5959171A (en) * | 1994-08-17 | 1999-09-28 | Pharming B.V. | Method for the production of biologically active polypeptides in a mammal's |
| US5635363A (en) * | 1995-02-28 | 1997-06-03 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for the detection, quantitation and purification of antigen-specific T cells |
| AU6184298A (en) * | 1997-02-25 | 1998-09-09 | Genzyme Transgenics Corporation | Transgenically produced non-secreted proteins |
| GB9708918D0 (en) * | 1997-05-01 | 1997-06-25 | Ppl Therapeutics Scotland Ltd | Methods |
| CA2330527A1 (en) * | 1998-06-15 | 1999-12-23 | Genzyme Transgenics Corporation | Erythropoietin analog-human serum albumin fusion |
-
2000
- 2000-09-18 KR KR1020027003537A patent/KR20020039346A/ko not_active Ceased
- 2000-09-18 NZ NZ517774A patent/NZ517774A/en unknown
- 2000-09-18 AU AU38831/01A patent/AU781462B2/en not_active Ceased
- 2000-09-18 CN CN00814422A patent/CN1379782A/zh active Pending
- 2000-09-18 HU HU0202702A patent/HUP0202702A2/hu unknown
- 2000-09-18 EP EP00963585A patent/EP1237900A4/en not_active Withdrawn
- 2000-09-18 MX MXPA02002768A patent/MXPA02002768A/es unknown
- 2000-09-18 CA CA002384766A patent/CA2384766A1/en not_active Abandoned
- 2000-09-18 BR BR0014524-6A patent/BR0014524A/pt not_active IP Right Cessation
- 2000-09-18 JP JP2001523619A patent/JP2003509038A/ja active Pending
- 2000-09-18 RU RU2002110116/13A patent/RU2002110116A/ru unknown
- 2000-09-18 WO PCT/US2000/025558 patent/WO2001019842A1/en not_active Ceased
- 2000-09-18 IL IL14854900A patent/IL148549A0/xx unknown
-
2002
- 2002-03-13 NO NO20021244A patent/NO20021244L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001019842A1 (en) | 2001-03-22 |
| CN1379782A (zh) | 2002-11-13 |
| NO20021244L (no) | 2002-05-13 |
| RU2002110116A (ru) | 2004-03-10 |
| HUP0202702A2 (hu) | 2002-12-28 |
| CA2384766A1 (en) | 2001-03-22 |
| NO20021244D0 (no) | 2002-03-13 |
| AU3883101A (en) | 2001-04-17 |
| EP1237900A1 (en) | 2002-09-11 |
| WO2001019842A9 (en) | 2002-11-14 |
| IL148549A0 (en) | 2002-09-12 |
| KR20020039346A (ko) | 2002-05-25 |
| BR0014524A (pt) | 2002-06-11 |
| AU781462B2 (en) | 2005-05-26 |
| NZ517774A (en) | 2005-01-28 |
| EP1237900A4 (en) | 2005-08-03 |
| MXPA02002768A (es) | 2002-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3659261B2 (ja) | 組換体タンパク質の多機能性複合体への標的化ヘテロ結合 | |
| JP3490437B2 (ja) | 単量体および二量体抗体フラグメント融合タンパク質 | |
| AU675223B2 (en) | Chimeric multivalent protein analogues and methods of use thereof | |
| US10894821B2 (en) | Activatable antibodies having non-binding steric moieties and methods of using the same | |
| CN102482347B (zh) | 修饰抗体组合物及其制备和使用方法 | |
| EP0108146B1 (en) | Fused genes encoding hybrid proteins, cloning vectors containing them and the use thereof | |
| JP2001506990A (ja) | 一価の（ｍｏｎｏｖａｌｅｎｔ）抗体フラグメント | |
| JP2001095566A (ja) | サイトカインの免疫複合体 | |
| JPH07501698A (ja) | 二価特異性ヘテロ二量体 | |
| JPH06505399A (ja) | 抗ヒト脂肪乳球人化抗体 | |
| JP2002512612A (ja) | 安定かつ活性なヒトＯＢタンパク質と抗体Ｆｃ鎖とのコンジュゲートを含む組成物および方法 | |
| IE902254L (en) | Bispecific and oligospecific mono- and oligovalent¹receptors, the preparation and use thereof | |
| JP2001503253A (ja) | 非抗原性即素複合体およびインターナライジング受容体システムの融合タンパク | |
| JPH03501440A (ja) | 免疫反応性ヘテロ鎖抗体 | |
| UA126021C2 (uk) | Домен фібронектину типу ііі, що зв'язується із сироватковим альбуміном | |
| JP2008535475A5 (enExample) | ||
| JPH0889278A (ja) | 遺伝子導入用修飾蛋白質及びその製法 | |
| JPH0721000B2 (ja) | 膀胱癌細胞の処置法 | |
| CN118221804A (zh) | 工程化抗体和包含工程化抗体的抗体-药物偶联物 | |
| JP2003509038A (ja) | サブユニット最適化された融合タンパク質 | |
| McCafferty et al. | Engineering therapeutic proteins | |
| JP2005518344A5 (enExample) | ||
| JPH05294994A (ja) | アクチノマイシンｄ複合体の製造方法 | |
| JPH10147597A (ja) | 可溶性ポリペプチド | |
| RU2004114878A (ru) | Агенты, увеличивающие аффинность |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040401 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040401 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070417 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070925 |